Clin Immunol

• 

  Publication Venue For

  • Cellular changes in eculizumab early responders with generalized myasthenia gravis..  231:108830. 2021
  • The interaction of anti-DNA antibodies with DNA antigen: Evidence for hysteresis for high avidity binding..  231:108848. 2021
  • The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease..  219:108541. 2020
  • The binding of SLE autoantibodies to mitochondria..  212:108349. 2020
  • Morbidity in an adenosine deaminase-deficient patient during 27 years of enzyme replacement therapy..  211:108321. 2020
  • Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors..  201:48-54. 2019
  • HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)..  200:66-70. 2019
  • IL-11 antagonist suppresses Th17 cell-mediated neuroinflammation and demyelination in a mouse model of relapsing-remitting multiple sclerosis..  197:45-53. 2018
  • Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation..  191:59-62. 2018
  • Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers..  191:10-20. 2018
  • The role of monogamous bivalency and Fc interactions in the binding of anti-DNA antibodies to DNA antigen..  166-167:38-47. 2016
  • A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins..  165:55-59. 2016
  • Combined immunodeficiency in the United States and Kuwait: Comparison of patients' characteristics and molecular diagnosis..  161:170-173. 2015
  • Effects of enzyme replacement therapy on immune function in ADA deficiency patient..  161:391-393. 2015
  • Cellular and molecular targeting for nanotherapeutics in transplantation tolerance..  160:14-23. 2015
  • The role of fractalkine (CX3CL1) in regulation of CD4(+) cell migration to the central nervous system in patients with relapsing-remitting multiple sclerosis..  157:121-132. 2015
  • The role of antigen specificity in the binding of murine monoclonal anti-DNA antibodies to microparticles from apoptotic cells..  154:178-187. 2014
  • Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses..  153:308-322. 2014
  • The effect of polyamines on the binding of anti-DNA antibodies from patients with SLE and normal human subjects..  153:94-103. 2014
  • The role of microparticles in the generation of immune complexes in murine lupus..  146:1-9. 2013
  • The origin and properties of extracellular DNA: from PAMP to DAMP..  144:32-40. 2012
  • Thymic microenvironment reconstitution after postnatal human thymus transplantation..  140:244-259. 2011
  • Thymus transplantation..  135:236-246. 2010
  • T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia..  132:145-152. 2009
  • Immunologic reconstitution during PEG-ADA therapy in an unusual mosaic ADA deficient patient..  130:162-174. 2009
  • Oligoclonal myelin-reactive T-cell infiltrates derived from multiple sclerosis lesions are enriched in Th17 cells..  130:133-144. 2009
  • Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN)..  129:115-122. 2008
  • Inflammatory bowel disease following solid organ transplantation..  128:287-293. 2008
  • Bromelain treatment decreases neutrophil migration to sites of inflammation..  128:66-74. 2008